WO2006024784A3 - Analogues d'aminoglycosides, leur utilisation pour le traitement des maladies microbiennes et leur synthese - Google Patents

Analogues d'aminoglycosides, leur utilisation pour le traitement des maladies microbiennes et leur synthese Download PDF

Info

Publication number
WO2006024784A3
WO2006024784A3 PCT/FR2005/002025 FR2005002025W WO2006024784A3 WO 2006024784 A3 WO2006024784 A3 WO 2006024784A3 FR 2005002025 W FR2005002025 W FR 2005002025W WO 2006024784 A3 WO2006024784 A3 WO 2006024784A3
Authority
WO
WIPO (PCT)
Prior art keywords
aminoglycoside
analogues
synthesis
treating microbial
microbial diseases
Prior art date
Application number
PCT/FR2005/002025
Other languages
English (en)
Other versions
WO2006024784A2 (fr
Inventor
Laurent Micouin
Frederic Francois Pierr Dardel
Carine Tisne-Vicrobeck
Frederique Maurice
Martine Bonin
Luna Alejandro Perez
Chloee Julie Bournaud
Guillaume Begis
Original Assignee
Univ Paris Descartes
Ct Nat De La Rech Scentifique
Laurent Micouin
Frederic Francois Pierr Dardel
Carine Tisne-Vicrobeck
Frederique Maurice
Martine Bonin
Luna Alejandro Perez
Chloee Julie Bournaud
Guillaume Begis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Paris Descartes, Ct Nat De La Rech Scentifique, Laurent Micouin, Frederic Francois Pierr Dardel, Carine Tisne-Vicrobeck, Frederique Maurice, Martine Bonin, Luna Alejandro Perez, Chloee Julie Bournaud, Guillaume Begis filed Critical Univ Paris Descartes
Publication of WO2006024784A2 publication Critical patent/WO2006024784A2/fr
Publication of WO2006024784A3 publication Critical patent/WO2006024784A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/44—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton bound to carbon atoms of the same ring or condensed ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/74—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/22—Cyclohexane rings, substituted by nitrogen atoms
    • C07H15/222—Cyclohexane rings substituted by at least two nitrogen atoms
    • C07H15/224—Cyclohexane rings substituted by at least two nitrogen atoms with only one saccharide radical directly attached to the cyclohexyl radical, e.g. destomycin, fortimicin, neamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La présente invention concerne l'utilisation de composés comprenant un cycle cyclopentane, substitué en positions (1) et (3) par des groupements aminés, primaires, secondaires ou tertiaires, identiques ou différents, éventuellement protégés par un groupement protecteur, lesdits groupements aminés étant en configuration cis, pour la préparation d'un médicament destiné au traitement des maladies microbiennes, telle que les infections bactériennes, les viroses ou les mycoses.
PCT/FR2005/002025 2004-08-03 2005-08-03 Analogues d'aminoglycosides, leur utilisation pour le traitement des maladies microbiennes et leur synthese WO2006024784A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0408574 2004-08-03
FR0408574A FR2874014B1 (fr) 2004-08-03 2004-08-03 Analogues d'aminoglycosides, leur utilisation et leur synthese

Publications (2)

Publication Number Publication Date
WO2006024784A2 WO2006024784A2 (fr) 2006-03-09
WO2006024784A3 true WO2006024784A3 (fr) 2006-06-29

Family

ID=34949344

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2005/002025 WO2006024784A2 (fr) 2004-08-03 2005-08-03 Analogues d'aminoglycosides, leur utilisation pour le traitement des maladies microbiennes et leur synthese

Country Status (2)

Country Link
FR (1) FR2874014B1 (fr)
WO (1) WO2006024784A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2950030A1 (fr) 2014-05-30 2015-12-03 Universite Paris Descartes Composes cycliques presentant une fonctionnalite 1,3 diamino a utiliser dans le traitement d'une infection a vih

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0571870A1 (fr) * 1992-05-29 1993-12-01 Bayer Ag Cyclopentane- et -pentène-bêta-amino-acides
WO1994017090A1 (fr) * 1993-01-20 1994-08-04 Glaxo Group Limited Derives de la 2,6-diaminopurine
WO1997009053A1 (fr) * 1995-09-08 1997-03-13 Scriptgen Pharmaceuticals, Inc. 2-desoxystreptamine en tant que charpente moleculaire pour preparer des molecules presentant une diversite fonctionnelle et spatiale, ainsi que compositions pharmaceutiques les contenant
WO2001028979A2 (fr) * 1999-10-19 2001-04-26 Abbott Laboratories Inhibiteurs des neuraminidases
WO2002036548A2 (fr) * 2000-10-30 2002-05-10 Bayer Aktiengesellschaft Procede de production stereoselective d'hydrazinocycloalcenes et de diaminocycloalcanes
WO2002068420A1 (fr) * 2001-02-24 2002-09-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Derives xanthine, fabrication et utilisations en tant qu'agents pharmaceutiques
WO2004087680A1 (fr) * 2003-03-31 2004-10-14 Taisho Pharmaceutical Co., Ltd. Nouveaux derives de quinazoline et leur utilisation therapeutique
WO2005026111A2 (fr) * 2003-09-08 2005-03-24 Northwestern University Inhibiteurs heteromatiques selectifs d'oxyde nitrique synthase neuronale

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0571870A1 (fr) * 1992-05-29 1993-12-01 Bayer Ag Cyclopentane- et -pentène-bêta-amino-acides
WO1994017090A1 (fr) * 1993-01-20 1994-08-04 Glaxo Group Limited Derives de la 2,6-diaminopurine
WO1997009053A1 (fr) * 1995-09-08 1997-03-13 Scriptgen Pharmaceuticals, Inc. 2-desoxystreptamine en tant que charpente moleculaire pour preparer des molecules presentant une diversite fonctionnelle et spatiale, ainsi que compositions pharmaceutiques les contenant
WO2001028979A2 (fr) * 1999-10-19 2001-04-26 Abbott Laboratories Inhibiteurs des neuraminidases
WO2002036548A2 (fr) * 2000-10-30 2002-05-10 Bayer Aktiengesellschaft Procede de production stereoselective d'hydrazinocycloalcenes et de diaminocycloalcanes
WO2002068420A1 (fr) * 2001-02-24 2002-09-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Derives xanthine, fabrication et utilisations en tant qu'agents pharmaceutiques
WO2004087680A1 (fr) * 2003-03-31 2004-10-14 Taisho Pharmaceutical Co., Ltd. Nouveaux derives de quinazoline et leur utilisation therapeutique
WO2005026111A2 (fr) * 2003-09-08 2005-03-24 Northwestern University Inhibiteurs heteromatiques selectifs d'oxyde nitrique synthase neuronale

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
A. HASEGAWA ET AL.: "Studies on Cyclitols-XII: New syntheses of 2-Deoxystreptamine and Triaminocyclohexanediols", TETRAHEDRON, vol. 25, 1969, pages 3567 - 3578, XP002322377 *
GONG H ET AL: "Duplex molecular strands based on the 3,6-diaminopyridazine hydrogen bonding motif: Amplifying small-molecule self-assembly preferences through preorganization and iterative arrangement of binding residues", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY 16 FEB 2005 UNITED STATES, vol. 127, no. 6, 16 February 2005 (2005-02-16), pages 1719 - 1725, XP002376578, ISSN: 0002-7863 *
J. M. MELLOR ET AL.: "Reductive Cleavage of the Nitrogen-Nitrogen Bond in Hydrazine Derivatives", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTION 1, vol. 12, 1984, pages 2927 - 2931, XP009045890 *
M.A. CLARK ET AL.: "Stereoselective Synthetic Approaches to Highly Substituted Cyclopentanes via Electrophilic Additions to Mono-, Di- and Trisubstituted Cyclopentenes", J. ORG. CHEM., vol. 65, no. 13, 2000, pages 4058 - 4069, XP002376577 *
MAJCHRZAK M.W. ET AL.: "Double Inversion of the Secondary Nitrogens in cis-Diaziridinocyclopentane", ORGANIC MAGNETIC RESONANCE, vol. 21, no. 11, 1983, pages 706 - 710, XP009065103 *
MITTENDORF J. ET AL: "NOVEL ANTIFUNGAL BETA-AMINO ACIDS: SYNTHESIS AND ACTIVITY AGAINST CANDIDA ALBICANS", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 13, no. 3, 10 February 2003 (2003-02-10), pages 433 - 436, XP002317979, ISSN: 0960-894X *
STORSBERG J ET AL: "PALLADIUM-CATALYZED REACTIONS, 3+ STEREOSELECTIVE PALADIUM-CATALYZED C-C COUPLING REACTIONS WITH A DIAZABICYCLOÄ2.2.1ÜHEPTENE", ADVANCED SYNTHESIS & CATALYSIS, WILEY VCH VERLAG, WEINHEIM, DE, vol. 343, no. 2, 2001, pages 177 - 180, XP001061865, ISSN: 1615-4150 *
SWAIN M L ET AL: "SYNTHESES OF 9ALPHA,11ALPHA-DIACYLAMINO-9,11-DIDEOXY-PROSTAGLANDIN F2ALPHA ANALOGUES", JOURNAL OF THE CHEMICAL SOCIETY, CHEMICAL COMMUNICATIONS, CHEMICAL SOCIETY. LETCHWORTH, GB, no. 16, 1981, pages 840 - 841, XP000955990, ISSN: 0022-4936 *

Also Published As

Publication number Publication date
WO2006024784A2 (fr) 2006-03-09
FR2874014A1 (fr) 2006-02-10
FR2874014B1 (fr) 2010-05-14

Similar Documents

Publication Publication Date Title
WO2008127364A3 (fr) Composés antiviraux et utilisation de ceux-ci
WO2008115281A3 (fr) Composés de traitement d'infections virales
WO2006127932A3 (fr) Purification de cinacalcet
WO2006039164A3 (fr) Nouveaux analogues de la cyclosporine et leurs utilisations pharmaceutiques
MX2010001733A (es) Compustos de imidazo[1,2-a]pirazina para tratamiento de infecciones virales tales como hepatitis.
TW200640908A (en) Chemical compounds
GB0128996D0 (en) Organic compounds
SE0200920D0 (sv) Novel compounds
WO2007076260A3 (fr) Agonistes de recepteur de farnesoide x
TW200613243A (en) Novel compounds
IL225529A0 (en) Fosfomycin/aminoglycoside combination in spray form for the treatment of bacterial infections of the respiratory tract
WO2006120563A3 (fr) Agents antibacteriens
WO2008064202A3 (fr) Formulations à libération modifiée de composés actifs vis-à-vis du récepteur de calcium
WO2008017381A8 (fr) Imidazolidin-2,4-dione arylaminoaryl-alkyl-substituée, son procédé de fabrication, médicament contenant ce composé et son utilisation
WO2008020227A3 (fr) Composés chimiques
IL172634A0 (en) Agent for inhibiting membrane virus reproduction, method for the production thereof pharmaceutical composition and method for inhibiting viral infections
WO2005005436A3 (fr) Antibiotiques de glycopeptide-cephalosporine reticules
TW200740781A (en) Novel compounds
WO2007048027A3 (fr) Combinaison de composes organiques
WO2003099217A3 (fr) Methodes de traitement d'infections bacteriennes et de maladies associees
DE602004024393D1 (de) Quervernetzte glycopeptid-cephalosporin-antibiotika
WO2006091836A8 (fr) Preparations de tartrate de ladostigil
WO2006130726A3 (fr) Utilisation du ladostigil pour traiter la sclerose en plaques
AU2003231833A1 (en) Cross-linked glycopeptide-cephalosporin antibiotics
IL160846A0 (en) Cross-linked glycopeptide-cephalosporin antibiotics

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase